title: Fish oil derivatives as a prophylaxis of recurrent miscarriage associated with antiphospholipid antibodies (APL): a pilot study.
abstract: Since 1989, 22 patients with persistent antiphospholipid syndrome (PAPS) associated with recurrent miscarriage (defined as three or more miscarriages) were treated with fish oil, equivalent to 5.1 g eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a ratio of 1.5 EPA to DHA. Twenty-two patients had 23 pregnancies (one patient had two pregnancies) over a period of 3 years. There was only one intrauterine fetal death at the 27th week associated with pre-eclampsia. Twenty-one pregnancies, 19 of which ended after the 37th week, produced a baby. Two pregnancies ended with cesarean section for pre-eclampsia at 30th and 35th week of gestation and one is ongoing at 32nd week. All babies are well. The weight at birth of babies delivered at term was always > 2500 g. These encouraging results favour a therapeutic role, without any adverse reaction, of fish oil to prevent recurrent miscarriage in PAPS.
authors.affiliation: Department of Haematology I, Ospedale S. Martino, Genova, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Rossi
authors.forename: M
authors.initials: M
authors.lastname: Costa
mesh_terms: D000026:Abortion, Habitual / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D000328:Adult; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000150:complications* / Q000178:diet therapy*; D001724:Birth Weight; D004281:Docosahexaenoic Acids / Q000008:administration & dosage; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage; D005260:Female; D005395:Fish Oils / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D015539:Platelet Activation / Q000187:drug effects; D011225:Pre-Eclampsia / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D011247:Pregnancy
chemical_list: D005395:Fish Oils; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid